
bluebird bio Investor Relations Material
Latest events

Q3 2024
bluebird bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from bluebird bio Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Product revenue
Other
Expenses by
Financials
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company's product portfolio comprises two clinical-stage lentiviral-based gene therapy product candidates for the treatment of transfusion-dependent b-thalassemia (TDT) and severe sickle cell disease (SCD); and a preclinical-stage gene therapy product candidate for the treatment of childhood cerebral adrenoleukodystrophy. Its clinical development programs include LentiGlobin BB305 program to treat TDT and SCD; and Lenti-D that is in Phase II/III trial to treat cerebral adrenoleukodystrophy. The company has collaboration agreements with Celgene Corporation; Intellia Therapeutics, Inc.; Catalent Biologics LLC; Kite Pharma, Inc.; Genethon S.A.; and University of Pennsylvania. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts
Key slides for bluebird bio Inc


Status Update
bluebird bio Inc


Status Update
bluebird bio Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
BLUE
Country
🇺🇸 United States